Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Catecholinergic ventricular tachycardia in children].

I Denjoy1, A Postma, J M Lupoglazoff

  • 1Cardiologie pédiatrique, hôpital Robert Debré, Paris. isabelle.denjoy@lrb.ap-hop-paris.fr

Archives Des Maladies Du Coeur Et Des Vaisseaux
|June 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastrointestinal and eating problems in SCN1A-related seizure disorders.

Epilepsy & behavior : E&B·2023
Same author

Printability and bio-functionality of a shear thinning methacrylated xanthan-gelatin composite bioink.

Biofabrication·2021
Same author

Shop until you drop: alternative interpretations.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Neural correlates of egocentric and allocentric frames of reference combined with metric and non-metric spatial relations.

Neuroscience·2019
Same author

High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations.

Scientific reports·2018
Same author

Life-long tailoring of diagnosis and management of patients with idiopathic ventricular fibrillation-future perspectives in research.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2018

Catecholinergic ventricular tachycardia, a genetic arrhythmia causing syncope and sudden death, is effectively managed with high-dose beta-blockers. Genetic testing for RyR2 mutations is crucial for identifying at-risk individuals and guiding treatment strategies.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatric Electrophysiology

Context:

  • Catecholinergic ventricular tachycardia (CVT) is a life-threatening adrenergic-induced polymorphic ventricular arrhythmia.
  • It primarily affects infants, causing syncope and sudden death without apparent cardiac abnormalities.
  • Untreated CVT carries a very high mortality rate.

Purpose:

  • To report genetic and clinical findings in 25 CVT cases presenting with syncope or sudden death.
  • To evaluate the efficacy of beta-blocker treatment and identify risk factors for adverse events.
  • To emphasize the importance of genetic studies in families with a high risk of sudden cardiac death.

Summary:

  • Analysis of 25 CVT cases and 41 affected family members revealed RyR2 gene mutations in a significant proportion.

Related Experiment Videos

  • High-dose beta-blocker therapy (nadolol) demonstrated 96% effectiveness in preventing major arrhythmic events during long-term follow-up.
  • Despite treatment, 12% experienced syncope or sudden death, necessitating consideration of automatic defibrillators in adolescents with a history of syncope or resuscitated sudden death.

    • Impact:

    • High-dose beta-blockers are effective in preventing serious arrhythmias in children with CVT.
    • Genetic screening for RyR2 mutations is vital for early diagnosis and risk stratification in affected families.
    • Implantable cardioverter-defibrillators should be considered for adolescent patients with a history of syncope or resuscitated sudden death due to CVT.